All AbMole products are for research use only, cannot be used for human consumption.
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.
Human ROR1 HEK293T cells were stained with Zilovertamab vedotin and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.05656 ug/ml.
Human ROR1 CHO-K Cell Line were stained with zilovertamab vedotin and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.03245 ug/mL.
Zilovertamab vedotin inhibited the tumor growth of MDA-MB-231on NSG mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 96.6% at 10 mpk.
| CAS Number | 2376463-48-6 |
| Storage | Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles. |
[1] Anita Kumar, et al. Am Soc Clin Oncol Educ Book. New Directions for Mantle Cell Lymphoma in 2022
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Talacotuzumab-MMAE
Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody. |
| Enfortumab vedotin-ejfv
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker. |
| Vandortuzumab vedotin
Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. |
| Farletuzumab MMAE
Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE. |
| Tisotumab Vedotin
Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
